BridgeBio Pharma (BBIO) stock has risen 29% in the past three months, primarily due to the strong performance of its heart medication, Attruby. The company's second-quarter Attruby sales more than tripled year-over-year, exceeding $222 million, with total revenue reaching nearly $244 million, more than double that of the same period in 2025. Furthermore, BridgeBio has submitted New Drug Applications (NDAs) for three late-stage development drugs to the U.S. Food and Drug Administration (FDA), two of which have been accepted. Analysts are generally optimistic about BridgeBio, with institutions like Piper Sandler raising their price targets.